Overview

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).
Phase:
Phase 1
Details
Lead Sponsor:
Cellectar Biosciences, Inc.
Collaborator:
National Cancer Institute (NCI)